CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Obeticholic Acid 10 MG +1 moredrug
Likely dose
Obeticholic Acid 10 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07104786
NCT07104786Phase 2Completed
CompareCT.gov

Effectiveness of Obeticholic Acid Versus Vitamin E in Patients of Non-alcoholic Fatty Liver Disease

King Edward Medical University·interventional·Posted Aug 5, 2025·Updated Aug 5, 2025

In Brief

A Phase 2 clinical trial evaluating Obeticholic Acid 10 MG and Vitamin E 400mg for Non Alcoholic Fatty Liver Disease. Completed, enrolled 90 participants across 1 site.

Detailed Summary

This study was conducted on patients presenting to Mayo Hospital, Lahore from 24th August, 2023 till 23rd May, 2024. Ninety patients conforming to the inclusion criteria were selected via simple random sampling technique and divided into two groups. Group A received Obeticholic acid 10mg once a day and Group B received Vitamin E 400mg twice a day. Both treatments were given for 6 months alongwith clear written and informed instructions regarding lifestyle modification. Patients were followed at 3 and 6 months with ultrasound abdomen and serum alanine transferase levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Alcoholic Fatty Liver Disease
CountriesPakistan
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedAug 5, 2025
Enrollment StartAug 24, 2023
Primary CompletionNov 23, 2023
Study CompletionMay 23, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11 months ago

Interventions

Obeticholic Acid 10 MGdrug

10mg OCA was given once daily for 6 months

Vitamin E 400mgdietary

Vitamin E 400mg was given twice daily for 6 months